2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 421

Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity
Abstract Number: 2903

Serum CC-Chemokine Ligand 18 Level Is a Potential Biomarker of Disease Activity in IgG4-Related Disease
Abstract Number: 1664

Serum FAS, Ferritin, Igfbp2, sTNFR2 As Markers for Tracking Mucocutaneous and Musculoskeletal Flares in SLE Patients
Abstract Number: 1380

Serum Galectin-3 in Rheumatoid Arthritis Compared with Healthy Controls and Subjects with Prediabetes before and after High-Intensity Interval Training
Abstract Number: 782

Serum IL-6, SAA and Calprotectin As Biomarkers in Giant Cell Arteritis and Polymyalgia Rheumatica
Abstract Number: 1895

Serum Interleukin 18 As a Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome and Use of Recombinant Human IL-18 BP in a Patient with Refractory Disease
Abstract Number: 1181

Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease
Abstract Number: 2728

Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients
Abstract Number: 426

Serum Levels of the Anti-TNF Biologics Correlate with Clinical Efficacy in Patients with Inflammatory Arthritis
Abstract Number: 2150

Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Abstract Number: 1774

Serum Periostin As a Biomarker in Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1389

Serum Progranulin Antibodies (PGRN-abs) in Rheumatoid Arthritis Patients Being Negative for RF-IgM and ACCP-IgG
Abstract Number: 2863

Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal
Abstract Number: 1431

Serum Trough Levels of Adalimumab Inversely Correlate with Disease Activity in Patients with Inflammatory Arthritis
Abstract Number: 2080

Serum Uric Acid and Incident Dementia: A Population Based Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].